Brief: Abliva And Owl Therapeutics Enter Licensing And Collaboration Agreement

Abliva AB

15/11/2023 06:56

Nov 15(Reuters) - Abliva AB  ABLI.ST :
    * SAID ON TUESDAY ABLIVA AND US-BASED OWL THERAPEUTICS ENTER
LICENSING AND COLLABORATION AGREEMENT FOR ABLIVA’S NEUROSTAT®
FOR TREATMENT OF TRAUMATIC BRAIN INJURY
    * OWL THERAPEUTICS, A CLINICAL-STAGE BIOPHARMACEUTICAL
COMPANY,
WILL RECEIVE A GLOBAL (EXCLUDING CHINA AND SOUTH KOREA) LICENSE
TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE NEUROSTAT
    * ABLIVA ELIGIBLE TO RECEIVE UP TO $43.65 MLN IN MILESTONES
(EXCLUDING ROYALTIES)
    * $1.15 MLN OF WHICH WILL BE PAID UPON REALIZATION OF
SPECIFIC
CLINICAL AND REGULATORY MILESTONES, WITH A FURTHER UP TO $42.5
MLN PAYABLE ON ACHIEVEMENT OF COMMERCIAL RELATED MILESTONES
    * ABLIVA ELIGIBLE FOR MID-SINGLE DIGIT ROYALTIES (BASED ON
NET
SALES) UPON COMMERCIALIZATION
    * OWL THERAPEUTICS RESPONSIBLE FOR ALL COSTS ASSOCIATED WITH
DEVELOPMENT, MANUFACTURE, AND COMMERCIALIZATION OF NEUROSTAT

        
 Source text for Eikon:  ID:nMFN9Y8ndh 
 Further company coverage:  ABLI.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))